

(PS2216) LETERMIVIR FOR CYTOMEGALOVIRUS PROPHYLAXIS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: THE RESULTS OF LETREAL STUDY.

Topic: 23. Stem cell transplantation - Clinical

Yi Xia^{*1}, Qi Wen¹, Jinfang Zhao¹, Xiaohui Zhang¹, Lanping Xu¹, Yu Wang¹, Chen-Hua Yan¹, Yu-Hong Chen¹, Wei Han¹, Feng-Rong Wang¹, Jing-Zhi Wang¹, Jun Kong¹, Tingting Han¹, Leqing Cao¹, Dao-Xing Deng¹, Xiao-Dong Mo¹

¹*Peking University People's Hospital, Beijing, China;*

Background

Letermovir is recommended for cytomegalovirus (CMV) prophylaxis after allogeneic hematopoietic stem cell transplantation (allo-HSCT), but its real-world effectiveness in patients receiving haploidentical related donor transplantation with antithymocyte globulin-based graft-versus-host disease (GVHD) prophylaxis remains inconclusive.

Aims

Thus, in the present real-world study, we aimed to further confirm the efficacy of letermovir prophylaxis in a large allo-HSCT cohort (letermovir prophylaxis in the real-world study, LETreal study) in which many of them received HIDs HSCT with ATG-based protocol for GVHD prophylaxis. We also aimed to further confirmed the association between letermovir prophylaxis and EBV infection after allo-HSCT.

Methods

We enrolled 1331 acute leukemia patients receiving allo-HSCT in Institute of Hematology, Peking University from January 2023 to March 2025, including 978 who received letermovir prophylaxis. Among them, 254 patients continued letermovir prophylaxis beyond day 100 post-transplant (median time to discontinuation: 119 days). The primary outcome was cs-CMV infection at 100 days and cs-CMV infection between 100 to 200 days after transplantation. Propensity score matching (PSM) was applied to balance baseline characteristics, including age at allo-HSCT (<16 years vs. 16-60 years vs. > 60 years), gender (male vs. female), donor-recipient relationship (matched sibling donor vs. haploidentical related donor vs. matched unrelated donor), and GVHD prophylaxis (without ATG vs. ATG).

Copyright Information: (Online) ISSN: 2572-9241

©2026 The Author(s). HemaSphere is published by John Wiley & Sons Ltd on behalf of European Hematology Association. This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND), which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially.

Abstract Book Citations: Authors, Title, HemaSphere, 2026;10;(S1):pages. The abstract book DOIs can be found on the "Author Information" page.

Disclaimer: Articles published in the journal HemaSphere exclusively reflect the opinions of the authors. The authors are responsible for all content in their abstracts including accuracy of the facts, statements, citing resources, etc.

Results

Among patients receiving letermovir, the 100-day cumulative incidences of cs-CMV infection (Figure), CMV disease, and refractory CMV infection were 7.1%, 0.1%, and 2.0%, respectively. After propensity score matching, letermovir prophylaxis significantly reduced the 100-day cumulative incidence of cs-CMV infection (7.0% vs. 18.6%, $P<0.001$) and refractory CMV infection (1.4% vs. 7.0%, $P=0.004$) compared with no prophylaxis. Letermovir also decreased 100-day cumulative incidence of cs-CMV infection in patients with grade II-IV acute GVHD and those with grade III-IV aGVHD.

Donor-/recipient+ CMV serostatus and age >60 years were associated with a higher risk of cs-CMV infection between days 100 and 200 after allo-HSCT in patients receiving letermovir prophylaxis. After PSM adjustment, patients receiving extended letermovir prophylaxis beyond day 100 experienced comparable late-onset cs-CMV infection, CMV disease and refractory cs-CMV infection between days 100 and 200 after allo-HSCT compared with those without letermovir. For patients experienced chronic GVHD or those experienced moderate-to-severe chronic GVHD, the cumulative incidence of cs-CMV infection between days 100 and 200 was also comparable.

In addition, patients receiving letermovir prophylaxis had significantly higher 2-year cumulative incidences of cs-EBV infection ($P<0.001$) and EBV-post-transplant lymphoproliferative disorder ($P=0.002$) compared with no prophylaxis.

After PSM adjustment, the 2-year clinical outcomes (relapse, non-relapse mortality, leukemia-free survival and overall survival) were comparable among patients among without letermovir and those receiving letermovir prophylaxis.

Summary/Conclusion


In summary, we comprehensive present the effectiveness of letermovir prophylaxis through a large allo-HSCT cohort in the real world, and we also confirmed that letermovir prophylaxis increased the risk of cs-EBV infection and PTLN after allo-HSCT.

Copyright Information: (Online) ISSN: 2572-9241

©2026 The Author(s). HemaSphere is published by John Wiley & Sons Ltd on behalf of European Hematology Association. This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND), which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially.

Abstract Book Citations: Authors, Title, HemaSphere, 2026;10;(S1):pages. The abstract book DOIs can be found on the "Author Information" page.

Disclaimer: Articles published in the journal HemaSphere exclusively reflect the opinions of the authors. The authors are responsible for all content in their abstracts including accuracy of the facts, statements, citing resources, etc.



The comparison of cs-CMV infection at 100 days after allo-HSCT after PSM adjusted. Allo-HSCT, allogeneic hematopoietic stem cell transplantation; TBI, total body irradiation; MSD, matched sibling donor; HID, haploidentical related donor; MUD, matched unrelated donor; GVHD, graft-versus-host disease; ATG, antithymocyte globulin; CMV, cytomegalovirus; EBV, Epstein-Barr virus; HR, hazard ratio; 95% CI, 95% confidence interval.

Copyright Information: (Online) ISSN: 2572-9241

©2026 The Author(s). HemaSphere is published by John Wiley & Sons Ltd on behalf of European Hematology Association. This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND), which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially.

Abstract Book Citations: Authors, Title, HemaSphere, 2026;10;(S1):pages. The abstract book DOIs can be found on the “Author Information” page.

Disclaimer: Articles published in the journal HemaSphere exclusively reflect the opinions of the authors. The authors are responsible for all content in their abstracts including accuracy of the facts, statements, citing resources, etc.